Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List due to downward revisions in earnings estimates for the current year Group 1: Company Summaries - adidas AG (ADDYY) is a sports lifestyle products company with a Zacks Consensus Estimate for its current year earnings revised downward by 6.4% over the last 60 days [1] - AptarGroup, Inc. (ATR) develops and manufactures drug delivery systems and has seen its Zacks Consensus Estimate for current year earnings revised downward by 5.8% over the last 60 days [1] - Canadian Natural Resources Limited (CNQ) is involved in crude oil, natural gas, and natural gas liquids, with its Zacks Consensus Estimate for current year earnings revised downward by 12.2% over the last 60 days [2]

Summary of AptarGroup FY Conference Call (March 03, 2026) Company Overview - **Company**: AptarGroup (NYSE:ATR) - **Industry**: Drug and consumer product packaging - **Core Business**: Design and manufacturing of dosing, dispensing, and protection technologies, with a focus on proprietary intellectual property [3][4] Financial Performance - **2025 Revenue**: Approximately $3.8 billion - **Pharma Segment**: 46% of revenue, 70% of adjusted EBITDA - **Beauty Segment**: 35% of revenue, 18% of adjusted EBITDA - **Closures Segment**: 19% of revenue, 13% of adjusted EBITDA [4] - **Capital Return**: $1.2 billion returned to shareholders over the last five years through dividends and share buybacks [6][14] - **Leverage Ratio**: 1.38x EBITDA, at the low end of the 1-3x corridor [5] Market Segments and Growth Opportunities - **Pharma Segment**: - Total Addressable Market (TAM): $165 billion, projected 7% CAGR - Revenue CAGR over the last 10 years: 9% [11][22] - Key products: Proprietary drug delivery systems (70% of pharma revenue), injectables (19%), active material science solutions (10%) [17] - Strong pipeline in respiratory, biologics, and systemic nasal drug delivery [24][25] - **Beauty Segment**: - Revenue: $1.3 billion in 2025, with 60% of sales in Europe - Growth: 7% total sales growth, 2% core sales growth [35][38] - Focus on innovation and serving both major and indie brands [38] - **Closures Segment**: - Revenue: $700 million, with 2% reported growth and 1% core growth [39] - Strong product volume growth of 4% when isolating resin pass-through impacts [41] Innovation and Technology - **Intellectual Property**: Over 7,300 patents, with 62% in pharma [10][18] - **Sustainability Leadership**: Recognized for sustainability efforts, which attract customers and talent [15][16] - **AI and Digital Health**: Incorporating AI for advanced analytics to enhance service offerings and strengthen customer relationships [53][54] Strategic Focus - **Investment Strategy**: Approximately two-thirds of capital returned to business through organic CapEx and M&A, with a focus on the pharma segment [13][14] - **Long-term Revenue Growth Target**: 4%-7% total revenue growth, supported by market growth projections [12][29] - **Customer Engagement**: Building relationships from the design phase through to patient engagement, enhancing revenue stickiness [30][32] Key Challenges and Considerations - **Emergency Medicine Reset**: Acknowledged impact on pharma growth, but overall strong growth in other areas [41] - **Market Dynamics**: Transition from high GWP to low GWP propellants in inhalers, with regulatory pressures influencing growth [46][47] Conclusion - **Outlook**: Positive growth trajectory across all segments, with a strong emphasis on innovation, sustainability, and leveraging technology to enhance customer value and operational efficiency [42][54]

Core Viewpoint - Cardinal Health, Inc. is poised to report strong fiscal second-quarter earnings for 2026, with significant growth in earnings per share (EPS) anticipated due to various strategic initiatives and market performance [1][2][5]. Financial Performance - Analysts expect Cardinal Health to report a profit of $2.31 per share on a diluted basis, reflecting a 19.7% increase from $1.93 per share in the same quarter last year [2]. - For the full fiscal year, EPS is projected to be $9.86, up 19.7% from $8.24 in fiscal 2025, with further growth expected to $10.90 in fiscal 2027, representing a year-over-year increase of 10.6% [3]. Stock Performance - Cardinal Health's stock has outperformed the S&P 500 Index, which gained 16.4% over the past 52 weeks, with CAH shares increasing by 74.3% during the same period [4]. - The company also significantly outperformed the Health Care Select Sector SPDR Fund, which returned 12.8% in the same timeframe [4]. Strategic Initiatives - The strong performance of Cardinal Health is attributed to the acquisition of Solaris Health, which added over 750 providers to its MSO platform, alongside robust organic growth in pharmaceuticals, generics, and specialty solutions [5]. - New customer acquisitions, effective cost controls, and investments in automation and logistics are enhancing profitability, with double-digit growth expected in specialty platforms such as autoimmune, urology, and oncology [5]. Recent Developments - On October 30, Cardinal Health shares rose more than 15% following the release of Q1 results, where adjusted EPS of $2.55 exceeded Wall Street expectations of $2.21, and revenue reached $64 billion, surpassing forecasts of $59.1 billion [6]. - The company anticipates full-year adjusted EPS to be in the range of $9.65 to $9.85 [6].